BGI ((BGI China) was founded in 1999 with the vision of using genomics to benefit mankind and has since become the largest genomic organization in the world. With a focus on research and applications in the healthcare, agriculture, conservation, and environmental fields, BGI has a proven track record of innovative, high profile research, which has generated over 2,137 publications, many in top-tier journals such as Nature and Science.
AUSTIN, Texas and SHENZHEN, China, June 24, 2021 /PRNewswire/ - Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, and BGI Genomics Co., Ltd., (300676.SZ), one of the world's leading genomics companies, today announced the launch of the BGI/Natera Signatera Assay which is now available to biopharmaceutical customers and clinicians across China.
Natera and BGI Genomics Announce $50M Partnership to Commercialize Signatera Oncology Test in China and to Develop Reproductive Health Tests in Select Markets on BGI's DNBseq™ Technology Platform | Natera
Company Description: Bgi Genomics Co., Ltd. is located in Shenzhen, Guangdong, China and is part of the Scientific Research and Development Services Industry. Bgi Genomics Co., Ltd. has 3,778 total employees across all of its locations and generates $1.28 billion in sales (USD). There are 65 companies in the Bgi Genomics Co., Ltd. corporate family.
BGI / BGI China (formerly known as Beijing Genomics Institute ) was founded in Beijing on Sept 9th, 1999 with the mission of supporting the development of science and technology, building strong research teams, and promoting the development of scientific partnership in genomics field.
High-profile China genomic sequencing company BGI and telecom network manufacturer and services company Huawei Technology plan a massive data-storage system for genomic research to achieve "an over 30% improvement in the overall efficiency of genome sequencing research tasks," according to a press release. The data will be used in applied genetic research.
ADDIS ABABA, Sept. 22 (Xinhua) -- Chen Songheng, General Manager of BGI Ethiopia, a subsidiary company of China's biotech giant, BGI Genomics Co., Ltd., is feeling optimistic about Ethiopia's anti-COVID-19 fight.
China's top gene-sequencing provider BGI will participate in the Genome Program, which aims to use genomic data to improve health outcomes in the United Arab Emirates (UAE), the company announced Wednesday.
"An attractive and dynamic business climate for high value-added products - indeed, that is what we see in Latvia." BGI, one of the world's largest genomics organizations, is a striking example of how LIAA attracts foreign investment and successful companies to Latvia.
NEW YORK - Building on an earlier licensing partnership, BGI Genomics and Natera have launched a clinical research program to use Signatera in China for colorectal cancer patients.
NEW YORK - Chinese diagnostics firm BGI Genomics reported last week that its H1 2021 revenues declined 11 percent due to decreasing demand for COVID-19 testing.
tommyru on 25 Feb 22BGI ((BGI China) was founded in 1999 with the vision of using genomics to benefit mankind and has since become the largest genomic organization in the world. With a focus on research and applications in the healthcare, agriculture, conservation, and environmental fields, BGI has a proven track record of innovative, high profile research, which has generated over 2,137 publications, many in top-tier journals such as Nature and Science.